90 related articles for article (PubMed ID: 24489398)
1. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
Duckett ME; Curran KM; Bracha S; Leeper HJ
J Am Anim Hosp Assoc; 2024 Jan; 60(1):7-14. PubMed ID: 38175982
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
Blaxill JE; Bennett PF
Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
[TBL] [Abstract][Full Text] [Related]
4. Mechlorethamine, vincristine, melphalan and prednisolone rescue chemotherapy protocol for resistant feline lymphoma.
Martin OA; Price J
J Feline Med Surg; 2018 Oct; 20(10):934-939. PubMed ID: 29065803
[TBL] [Abstract][Full Text] [Related]
5. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma.
Saba CF; Fan TM; Phillips BS; Wright ZM; Thamm DH
Vet Comp Oncol; 2024 Jun; 22(2):278-283. PubMed ID: 38616055
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of factors influencing survival time in 77 dogs with lymphoma.
Jeong SY
Open Vet J; 2023 Sep; 13(9):1124-1134. PubMed ID: 37842100
[TBL] [Abstract][Full Text] [Related]
7. Novel Treatments for Lymphoma.
Thamm DH
Vet Clin North Am Small Anim Pract; 2024 May; 54(3):477-490. PubMed ID: 38199913
[TBL] [Abstract][Full Text] [Related]
8. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma.
Sztukowski KE; Yaufman Z; Cook MR; Aarnes TK; Husbands BD
J Vet Intern Med; 2024; 38(3):1686-1692. PubMed ID: 38563346
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial.
Jones BS; Liebel FX; Fadda A; Martin S; Lawn R; Lazzerini K; Harcourt-Brown T
J Vet Intern Med; 2024; 38(3):1618-1625. PubMed ID: 38700360
[TBL] [Abstract][Full Text] [Related]
10. Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation.
Best MP; Straw RC; Gumpel E; Fry DR
J Vet Intern Med; 2023; 37(6):2368-2374. PubMed ID: 37700548
[TBL] [Abstract][Full Text] [Related]
11. Large granular lymphocyte lymphoma in 65 dogs (2005-2023).
Yale AD; Crawford AL; Gramer I; Guillén A; Desmas I; Holmes EJ
Vet Comp Oncol; 2024 Mar; 22(1):115-124. PubMed ID: 38156420
[TBL] [Abstract][Full Text] [Related]
12. Comparison of chemotherapy outcomes between normal and high serum cortisol concentration in dogs with lymphoma.
Yamazaki H; Bunbai K; Deguchi T; Tamura M; Ohota H
J Vet Intern Med; 2024; 38(3):1651-1658. PubMed ID: 38471970
[TBL] [Abstract][Full Text] [Related]
13. Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma.
Callegari AJ; Tsang J; Park S; Swartzfager D; Kapoor S; Choy K; Lim S
Front Oncol; 2024; 14():1304144. PubMed ID: 38390257
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Treggiari E; Elliott JW; Baines SJ; Blackwood L
Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
[TBL] [Abstract][Full Text] [Related]
16. A dexamethasone, melphalan, actinomycin-D and cytarabine chemotherapy protocol as a rescue treatment for feline lymphoma.
Elliott J; Finotello R
Vet Comp Oncol; 2018 Mar; 16(1):E144-E151. PubMed ID: 29044884
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
18. Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML; Suter SE; Hauck ML; Hess PR
Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer.
Matsuyama A; Woods JP; Mutsaers AJ
Can Vet J; 2017 Jan; 58(1):51-55. PubMed ID: 28042155
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Tanis JB; Mason SL; Maddox TW; Blackwood L; Killick DR; Amores-Fuster I; Harper A; Finotello R
Vet Comp Oncol; 2018 Sep; 16(3):361-369. PubMed ID: 29380942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
